NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $359.58 -0.58 (-0.16%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About United Therapeutics Stock (NASDAQ:UTHR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get United Therapeutics alerts:Sign Up Key Stats Today's Range$357.98▼$363.9050-Day Range$348.65▼$410.0052-Week Range$208.62▼$417.82Volume1.01 million shsAverage Volume449,066 shsMarket Capitalization$16.05 billionP/E Ratio15.79Dividend YieldN/APrice Target$370.86Consensus RatingModerate Buy Company OverviewUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More… United Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks94th Percentile Overall ScoreUTHR MarketRank™: United Therapeutics scored higher than 94% of companies evaluated by MarketBeat, and ranked 62nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 12 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageUnited Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth13.68% Earnings GrowthEarnings for United Therapeutics are expected to grow by 13.68% in the coming year, from $25.22 to $28.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 15.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.74.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 15.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.03.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 1.05. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.75% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in United Therapeutics has recently decreased by 5.88%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-2.00 Percentage of Shares Shorted4.75% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in United Therapeutics has recently decreased by 5.88%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.91 News SentimentUnited Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for United Therapeutics this week, compared to 10 articles on an average week.Search Interest13 people have searched for UTHR on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -36% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,547,253.00 in company stock.Percentage Held by Insiders11.90% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Stock News HeadlinesWho wants a pig organ? Patients sick and tired of waiting years for a transplantPeople worried they'll never get a scarce human transplant want to know when they might get a pig kidney insteadDecember 17, 2024 | marketbeat.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) EVP Sells 7,700 Shares of StockDecember 7, 2024 | insidertrades.comDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. December 22, 2024 | Crypto 101 Media (Ad)United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 7,700 SharesNovember 23, 2024 | insidertrades.comLouis W. Sullivan Sells 26,209 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockDecember 22 at 4:19 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Downgraded to "Buy" Rating by StockNews.comDecember 21 at 3:17 AM | americanbankingnews.comInsider Sell: Louis Sullivan Sells 26,209 Shares of United Therapeutics CorpDecember 19 at 7:30 PM | gurufocus.comCautious Hold: United Therapeutics’ Promising UKidney Progress Amidst Regulatory HurdlesDecember 18, 2024 | markets.businessinsider.comSee More Headlines UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $219.89 at the start of the year. Since then, UTHR stock has increased by 63.5% and is now trading at $359.58. View the best growth stocks for 2024 here. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. United Therapeutics's revenue was up 22.9% compared to the same quarter last year. Who are United Therapeutics' major shareholders? Top institutional shareholders of United Therapeutics include Wellington Management Group LLP (7.10%), State Street Corp (5.01%), Geode Capital Management LLC (2.45%) and FMR LLC (2.41%). Insiders that own company stock include Paul A Mahon, James Edgemond, Nilda Mesa, Judy D Olian, Louis W Sullivan, Christopher Causey, Michael Benkowitz, Raymond Dwek, Martine A Rothblatt and Christopher Patusky. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings10/30/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$370.86 High Stock Price Target$600.00 Low Stock Price Target$280.00 Potential Upside/Downside+3.1%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$22.77 Trailing P/E Ratio15.79 Forward P/E Ratio14.26 P/E Growth1.05Net Income$984.80 million Net Margins40.31% Pretax Margin52.17% Return on Equity19.22% Return on Assets16.15% Debt Debt-to-Equity RatioN/A Current Ratio4.58 Quick Ratio4.41 Sales & Book Value Annual Sales$2.76 billion Price / Sales5.82 Cash Flow$21.95 per share Price / Cash Flow16.38 Book Value$127.35 per share Price / Book2.82Miscellaneous Outstanding Shares44,645,000Free Float39,332,000Market Cap$16.05 billion OptionableOptionable Beta0.54 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:UTHR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.